Efficacy and Safety of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia

Michael Davidson, Jay Saoud, Corinne Staner, Nadine Noel, Sandra Werner, Elisabeth Luthringer, David Walling, Mark Weiser, Philip D. Harvey, Gregory P. Strauss, Remy Luthringer

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND: This is a placebo-controlled multi-national trial of roluperidone, a compound with antagonist properties for 5-HT2A, sigma2, and α1A-adrenergic receptors, targeting negative symptoms in patients with schizophrenia. This trial follows a previous trial that demonstrated roluperidone superiority over placebo in a similar patient population. METHODS: Roluperidone 32 mg/day, roluperidone 64 mg/day, or placebo was administered for 12 weeks to 513 patients with schizophrenia with moderate to severe negative symptoms. The primary endpoint was the PANSS-derived Negative Symptom Factor Score (NSFS) and the key secondary endpoint was Personal and Social Performance scale (PSP) total score. RESULTS: NSFS scores were lower (improved) for roluperidone 64 mg compared to placebo and marginally missing statistical significance for the intent-to-treat (ITT) analysis data set (P ≤ .064), but reached nominal significance (P ≤ .044) for the modified-ITT (m-ITT) data set. Changes in PSP total score were statistically significantly better on roluperidone 64 mg compared to placebo for both ITT and m-ITT (P ≤ .021 and P ≤ .017, respectively). CONCLUSIONS: Results of this trial confirm the potential of roluperidone as a treatment of negative symptoms and improving everyday functioning in patients with schizophrenia. Study registration: Eudra-CT: 2017-003333-29; NCT03397134.

Original languageEnglish
Pages (from-to)609-619
Number of pages11
JournalSchizophrenia Bulletin
Volume48
Issue number3
DOIs
StatePublished - 7 May 2022

Keywords

  • negative symptoms
  • schizophrenia
  • treatment

Fingerprint

Dive into the research topics of 'Efficacy and Safety of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia'. Together they form a unique fingerprint.

Cite this